Fundraising FoxIcosavax
Seattle, US · Founded 2017 · Delaware corporation · 6 known investors
Find your way into Icosavax
Sign up to see every warm intro you have to Icosavax
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Icosavax team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vaccine development platform using computationally designed synthetic virus-like particles
Founders & leadership
CR
Charles RichardsonSenior Vice President, Technical Operations
AK
Adam K. SimpsonPresident and Chief Executive Officer
NK
Niranjan Kanesa-thasanChief Medical Officer
DA
Douglas A. HoltzmanChief Scientific Officer and Secretary
CC
Cassia CearleyTreasurer, Chief Business Officer
Board
PK
MM
TG
Terry GouldBoard director
EM
Eric MoessingerBoard director
JH
TY
Tadataka Yamada, M.D.Chairman of the Board
Investors · 6
Qiming Venture Partners USAlisted by Qiming Venture Partners USACambridge
How we know: Qiming Venture Partners USA's portfolio page · Not right? Tell us
RA Capitallisted by RA CapitalBostonvia Peter Kolchinsky · board
How we know: RA Capital's portfolio page · board seat on SEC Form D · Not right? Tell us
Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$129.7M disclosed across 2 rounds · 2019–2021
▶$99.7MraisedApr 2021 · 36 investors · BiotechnologyRule 506(b)
▶$99.7MraisedApr 2021 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter KolchinskyDirector
- Charles RichardsonExecutive Officer
- Mark McDadeDirector
- Terry GouldDirector
- Adam K. SimpsonDirector, Executive Officer
- Eric MoessingerDirector
- Niranjan Kanesa-thasanExecutive Officer
- Douglas A. HoltzmanExecutive Officer
- Jason HaflerDirector
- Cassia CearleyExecutive Officer
- Tadataka Yamada, M.D.Director
- Offering amount
- $99.7M
- Amount sold
- $99.7M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$30MraisedOct 2019 · 22 investors · BiotechnologyRule 506(b)
▶$30MraisedOct 2019 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terry GouldDirector
- Jason HaflerDirector
- Eric MoessingerDirector
- Niranjan Kanesa-thasanExecutive Officer
- Adam K. SimpsonExecutive Officer, Director
- Mark McDadeDirector
- Charles RichardsonExecutive Officer
- Douglas A. HoltzmanExecutive Officer
- Tadataka Yamada, M.D.Director
- Offering amount
- $51M
- Amount sold
- $30M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Icosavax do?
- Vaccine development platform using computationally designed synthetic virus-like particles
- Who are Icosavax's investors?
- Icosavax's investors include Qiming Venture Partners USA, RA Capital, Sanofi Ventures, Viking Global, Qiming Healthcare, Qiming Venture Partners.
- How much funding has Icosavax raised?
- Icosavax has disclosed $129.7M raised across 2 rounds.
- Where is Icosavax headquartered?
- Icosavax is headquartered in Seattle, US.